Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder
|
Luke Timmerman |
11/20/09 |
Boston
|
|
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore
|
Luke Timmerman |
11/19/09 |
Boston
|
|
Student Dissertation Launches San Diego Life Sciences Tools Company, Sirigen
|
Denise Gellene |
11/04/09 |
San Diego
|
|
Biogen Shares Drop as Tysabri PML Cases Climb to 23, Europe May Seek Drug ‘Holiday’
|
Luke Timmerman |
10/23/09 |
Boston
|
|
Faster, Cheaper Stem Cells: Fate Therapeutics Co-Founder, With Scripps Team, Finds Key
|
Luke Timmerman |
10/18/09 |
National
|
|
Eastbourne Dumps Amylin Shares, Illumina Inks Licensing Deal, Avanir Releases Pseudobulbar Affect Data, & More San Diego Life Sciences News
|
Denise Gellene |
10/15/09 |
San Diego
|
|
Sirtris Advancing No. 1 Drug into Mid-Stage Clinical Trials for Type 2 Diabetes
|
Ryan McBride |
10/14/09 |
Boston
|
|
AVI Settles In, ZymoGenetics MS Drug Fails, Dendreon’s FDA Filing Set for Mid-November & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/01/09 |
Seattle
|
|
ZymoGenetics Partner Halts Multiple Sclerosis Trials After Drug Fails
|
Luke Timmerman |
09/28/09 |
Seattle
|
|
Ambrx Strikes Deal With Wyeth (Soon-to-be Pfizer) to Make Antibody Drugs
|
Luke Timmerman |
09/18/09 |
San Diego
|
|
Zymo Drug Fails Arthritis Trials
|
Luke Timmerman |
09/10/09 |
Seattle
|
|
Facet Rejects Biogen Takeover Bid
|
Luke Timmerman |
09/08/09 |
Boston
|
|
Biogen Idec Makes Hostile $350M Takeover Bid for Facet Biotech
|
Luke Timmerman |
09/04/09 |
Boston
|
|
Elan Breached Tysabri Partnership With Biogen Idec, Federal Judge Says
|
Luke Timmerman |
09/04/09 |
Boston
|
|
Avanir’s Results for Neurological Drug Triggers Outburst in Trading
|
Bruce V. Bigelow |
08/11/09 |
San Diego
|
|
Protecting America’s Leadership in Biotech Discovery
|
James N. Thomas |
08/06/09 |
Seattle
|
|
Biotech Pioneer Phillip Sharp Retires from Biogen Idec Board
|
Ryan McBride |
07/16/09 |
Boston
|
|
Kineta Acquires Multiple Sclerosis, Diabetes Drug Candidates to Test Unusual Biotech Strategy
|
Luke Timmerman |
07/08/09 |
Seattle
|
|
Biogen Gets Int’l Rights to Acorda’s MS Drug
|
Roxanne Palmer |
07/01/09 |
Boston
|
|
Biogen Reports 10th PML Case in Tysabri Patient
|
Roxanne Palmer |
06/29/09 |
Boston
|
|
EMD Serono Staging Battle Against Multiple Sclerosis in Boston, Chief Says
|
Ryan McBride |
06/08/09 |
Boston
|
|
Exclusive: Icahn’s Picks For Biogen Idec Board on Why They Think They Won 2 Seats, Who’s Likely Out, and Plans for the Future
|
Robert Buderi |
06/04/09 |
Boston
|
|
Icahn Nominees Claim Victory on Two of Four Open Seats to Biogen Idec Board, Vote Still Not Official
|
Roxanne Palmer |
06/03/09 |
Boston
|
|
Inside the Biogen Idec Shareholder Meeting, Tensions Flare as Icahn Accuses Company of “Hijacking” Vote
|
Roxanne Palmer |
06/03/09 |
Boston
|
|
Contentious Biogen Idec Meeting Delayed; Icahn Nominee Objects, Saying “This is Not North Korea”
|
Luke Timmerman |
06/03/09 |
Boston
|
|
Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today
|
Luke Timmerman |
06/03/09 |
Boston
|
|
Icahn Wins Key Endorsement In Proxy Fight With Biogen Idec
|
Luke Timmerman |
05/26/09 |
Boston
|
|
Icahn’s Plan to Split Up Biogen Idec Would “Destroy Shareholder Value,” Company Says
|
Luke Timmerman |
05/15/09 |
Boston
|
|
Avila Therapeutics Hires First CEO Katrine Bosley, Adds $5M from Existing Investors
|
Ryan McBride |
05/15/09 |
Boston
|
|
Biogen Idec Pipeline Strong, Tysabri Coming Back; Icahn Would “Weaken” Board, Company Says
|
Luke Timmerman |
05/14/09 |
Boston
|
|
Page 1 of
3 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
